enVVeno Medical (NASDAQ:NVNO) Stock Rating Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of enVVeno Medical (NASDAQ:NVNO) from a hold rating to a sell rating in a research note issued to investors on Sunday,Wall Street Zen reports.

A number of other brokerages have also commented on NVNO. LADENBURG THALM/SH SH upgraded shares of enVVeno Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, July 6th. Zacks Research raised shares of enVVeno Medical to a “hold” rating in a research report on Tuesday, July 7th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of enVVeno Medical in a research note on Friday, September 25th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold”.

enVVeno Medical Price Performance

Shares of NASDAQ:NVNO opened at $6.73 on Friday. The stock’s 50 day moving average price is $8.96 and its 200 day moving average price is $10.32. The stock has a market cap of $4.64 million, a price-to-earnings ratio of -0.35 and a beta of 1.41. enVVeno Medical has a 12 month low of $6.52 and a 12 month high of $25.90.

enVVeno Medical (NASDAQ:NVNO) last announced its quarterly earnings results on Thursday, October 29th. The company reported ($6.29) EPS for the quarter, missing the consensus estimate of ($3.27) by ($3.02). On average, sell-side analysts expect that enVVeno Medical will post -16.19 EPS for the current year.

About enVVeno Medical

enVVeno Medical Corporation (NASDAQ:NVNO) is a late-stage medical device company focused on developing bioprosthetic, or tissue-based, treatments for venous disease. Its primary focus is chronic venous insufficiency, a condition in which damaged or absent valves allow blood to flow backward in the veins and can cause swelling, pain, skin changes and ulcers.

The company’s lead product is the VenoValve, a surgically implanted bioprosthetic valve designed to restore one-way blood flow in the deep veins of the leg.